Sandoz Study Supports Expanded Use of Biosimilar Pegfilgrastim
May 5th 2020Expanding access to biosimilar pegfilgrastim (Ziextenzo) for patients at intermediate risk of febrile neutropenia and converting patients at high risk who are on the reference product (Neulasta) could save millions in healthcare costs, according to new study results.